US drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war ...

From late next month, the University of Adelaide and the University of South Australia will begin to cease operations and ...

ISLAMABAD: The Competition Commission of Pakistan (CCP) has authorized the acquisition of Novartis Pharma (Pakistan) Limited ...

For Strong, an enticing prospect might be blending ITV's heritage in free-to-air broadcasting with Sky's subscription-based ...

Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's ...

Opengate, a nonprofit organization headquartered in Westchester County, which provides support for people with disabilities throughout the lower Hudson Valley, ...

Paramount has decided to move on from Star Trek's Kelvin Timeline cast, and for many reasons, that is for the best.

During the week, investors were mostly active in the engineering sector, which accounted for 13.3% of total turnover, followed by the pharmaceuticals sector at 12.3% and the textile sector at 9.8%.

Pfizer has won a $10 billion deal to acquire obesity drug developer Metsera, securing foothold in lucrative weight-loss ...

Revised transaction values Metsera at up to $86.25 per share -- Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger ...

Homes sold in 16 days, spending three days or 23.1%, longer on the market than October 2024. Central Indiana experienced a 24 ...